Clinical trials: Advanced Biliary Tract Carcinoma
Biliary Tract Cancer
Study of Combination Therapy of D07001-Softgel Capsules and Xeloda/TS-1 in Subjects With Advanced Biliary Tract Cancer
The primary objective are: To assess the safety and tolerability of the combination of D07001-softgel capsules and Xeloda/TS-1. To evaluate the efficacy of the combination of D07001-softgel capsules and Xeloda/TS-1, as assessed…
- Trial name
- NCT05065957
- Testing
- D07001-softgel capsules + Xeloda (or TS-1), mFOLFOX
- Where
- 5 sites in Taiwan
- Volunteers
- 180 people
- Sponsor
- InnoPharmax Inc.
Bile Duct Adenocarcinoma, Stage III Intrahepatic Cholangiocarcinoma
Capecitabine and Y-90 Radioembolization in Treating Patients With Advanced Bile Duct Cancer in the Liver That Cannot Be Removed by Surgery
This phase I trial studies the side effects of capecitabine and Y-90 radioembolization in treating patients with bile duct cancer in the liver that has spread to other places in the body and cannot be removed by surgery.
- Conditions
- Bile Duct Adenocarcinoma, Stage III Intrahepatic Cholangiocarcinoma, Stage IVA Intrahepatic Cholangiocarcinoma, Stage IVB Intrahepatic Cholangiocarcinoma
- Trial name
- NCT03117855
- Testing
- Capecitabine, Laboratory Biomarker Analysis, Radioembolization
- Where
- United States
- Sponsor
- City of Hope Medical Center
Biliary Tract Cancer
Lenvatinib Combined With PD-1 Inhibitors as First-line Treatment for Unresectable/Advanced Biliary Tract Carcinoma
This is a multi-center, single-arm,phase Ⅱ study to evaluate the efficacy and safety of Lenvatinib in combination with PD-1 inhibitors as first-line treatment in patients with unresectable advanced Biliary Tract Carcinoma (BTC)
- Trial name
- LEADER-001 (NCT05509478)
- Testing
- Lenvatinib, PD-1 inhibitors
- Where
- China
- Volunteers
- 46 people
- Sponsor
- The First Hospital of Jilin University
Biliary Tract Cancer, Cholangiocarcinoma
Biomarker Discovery in Patients With Advanced Biliary Tract Cancer
Biliary tract cancer is a rare gastrointestinal malignant neoplasm and includes intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, and gall bladder cancer.
- Conditions
- Biliary Tract Cancer, Cholangiocarcinoma, Gallbladder Cancer
- Trial name
- NCT04871321
- Testing
- nab-paclitaxel plus gemcitabine-cisplatin
- Where
- South Korea
- Volunteers
- 119 people
- Sponsor
- CHA University
Biliary Tract Cancer, PD-1 Antibody
Tislelizumab（Anti PD-1), Lenvatinib and GEMOX Transformation in the Treatment of Potentially Resectable, Locally Advanced Biliary Tract Cancer
The aim of this study is to assess the R0 resection rate of tislelizumab combined with Lenvatinib and Gemox chemotherapy in the conversion therapy of potentially resectable locally advanced BTC.
- Conditions
- Biliary Tract Cancer, PD-1 Antibody, Gemox, Lenvatinib
- Trial name
- NCT05156788
- Testing
- PD-1+Lenvatinib+GEMOX
- Where
- 2 sites in China
- Volunteers
- 40 people
- Sponsor
- Shanghai Zhongshan Hospital
Locally Advanced Malignant Solid Neoplasm, Locally Advanced Unresectable Cholangiocarcinoma
Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies
This phase I/II trial studies the best dose and side effects of peposertib and to see how well it works with avelumab and hypofractionated radiation therapy in treating patients with solid tumors and hepatobiliary malignancies…
- Conditions
- Locally Advanced Malignant Solid Neoplasm, Locally Advanced Unresectable Cholangiocarcinoma, Locally Advanced Unresectable Gallbladder Carcinoma, Locally Advanced Unresectable Malignant Solid Neoplasm
- Trial name
- NCT04068194
- Testing
- Avelumab, Biopsy Procedure, Biospecimen Collection
- Where
- 46 sites in United States
- Volunteers
- 103 people
- Sponsor
- National Cancer Institute (NCI)